Catalent (CTLT) Announces Board Changes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Catalent Announces Changes to its Board of Directors
December 19, 2022 8:00 AM ESTBoard of Directors Selects J. Martin Carroll as Next Chair
Executive Chair John Chiminski and Directors Rolf Classon and Peter Zippelius to Retire
SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that current board member and lead independent director J. Martin (Marty) Carroll has been unanimously selected by its Board of Directors to succeed John... More
